INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

被引：4
|
作者：
Fujiwara, Yutaka [1 ]
Shitara, Kohei [2 ]
Shimizu, Toshio [1 ]
Yonemori, Kan [1 ]
Matsubara, Nobuaki [2 ]
Ohno, Izumi [2 ]
Kogawa, Takahiro [2 ]
Naito, Yoichi [2 ]
Leopold, Lance [3 ]
Sasahara, Kahori [4 ]
Yatsuzuka, Naoyoshi [4 ]
Takami, Tomoko [4 ]
Shimamoto, Takashi [4 ]
Yamamoto, Noboru [1 ]
Doi, Toshihiko [2 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Incyte Corp, Wilmington, DE USA
[4] MSD KK, Tokyo, Japan
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A204
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
    Doi, Toshihiko
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Munteanu, Mihaela
    Yatsuzuka, Naoyoshi
    Han, Shi Rong
    Samkari, Ayman
    Yamamoto, Noboru
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 152 - 162
  • [2] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
    Toshihiko Doi
    Yutaka Fujiwara
    Kohei Shitara
    Toshio Shimizu
    Kan Yonemori
    Nobuaki Matsubara
    Izumi Ohno
    Takahiro Kogawa
    Yoichi Naito
    Lance Leopold
    Mihaela Munteanu
    Naoyoshi Yatsuzuka
    Shi Rong Han
    Ayman Samkari
    Noboru Yamamoto
    Investigational New Drugs, 2021, 39 : 152 - 162
  • [3] Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma
    Gajewski, Thomas F.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Kaufman, David R.
    Zhao, Yufan
    Maleski, Janet
    Leopold, Lance
    Gangadhar, Tara C.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [4] Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
    Gibney, G.
    Hamid, O.
    Lutzky, J.
    Olszanski, A.
    Gangadhar, T.
    Gajewski, T.
    Chmielowski, B.
    Hanks, B.
    Boasberg, P.
    Zhao, Y.
    Newton, R.
    Bowman, J.
    Maleski, J.
    Leopold, L.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S106 - S107
  • [5] First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
    Beatty, Gregory L.
    O'Dwyer, Peter J.
    Clark, Jason
    Shi, Jack G.
    Bowman, Kevin J.
    Scherle, Peggy A.
    Newton, Robert C.
    Schaub, Richard
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3269 - 3276
  • [6] KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer
    Yamamoto, Noboru
    Satouchi, Miyako
    Doi, Toshihiko
    Fujiwara, Yutaka
    Yanagitani, Noriko
    Kawa, Yoshitaka
    Yoh, Kiyotaka
    Leopold, Lance
    Munteanu, Mihaela
    Sawada, Takashi
    Han, Shirong
    Noguchi, Kazuo
    Nishio, Makoto
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 261 - 271
  • [7] Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
    Powderly, John D.
    Klempner, Samuel J.
    Naing, Aung
    Bendell, Johanna
    Garrido-Laguna, Ignacio
    Catenacci, Daniel V. T.
    Taylor, Matthew H.
    Lee, James J.
    Zheng, Fred
    Zhou, Feng
    Gong, Xiaohua
    Gowda, Hema
    Beatty, Gregory L.
    ONCOLOGIST, 2022, 27 (11): : 905 - E848
  • [8] Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
    Vaishampayan, Ulka N.
    Fishman, Mayer N.
    Cho, Daniel C.
    Hoimes, Christopher J.
    Velcheti, Vamsidhar
    McDermott, David F.
    Slichenmyer, William J.
    Putiri, Emily
    Losey, Heather
    Rossi, Sean
    Ernstoff, Marc S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
    Mitchell, Tara C.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Schmidt, Emmett V.
    Zhao, Yufan
    Gong, Xiaohua
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3223 - +
  • [10] Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma
    Fujiwara, Yutaka
    Takahashi, Yasuo
    Okada, Morihito
    Kishimoto, Takumi
    Kondo, Shunsuke
    Fujikawa, Koshi
    Hayama, Manabu
    Sugeno, Masatoshi
    Ueda, Shinya
    Komuro, Keiko
    Lanasa, Mark
    Nakano, Takashi
    ONCOLOGIST, 2022, 27 (09): : E703 - E722
12345